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Summary Valproic acid (VPA) is an effective and widely used anticonvulsant,
associated with metabolic adverse effects such as weight gain, hyperinsulinemia,
hyperleptinemia and hypoadiponectinemia. The aim of this study was to evaluate the
influence of VPA and topiramate (TPM) on adiponectin binding receptors, adipoR1 and
adipoR2, in human liver cancer cells, HepG2. AdipoR1 but not adipoR2 gene expres-
sion was upregulated by VPA treatment. TPM did neither affect adipoR1 nor adipoR2
gene expression. Given the tight association between VPA treatment, metabolic side
effects and the adipocytokine-axis, upregulation of adipoR1 possibly represents a
favoured and insulin-sensitizing mechanism.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Valproic acid (VPA) is an effective anticonvulsant for
many types of epilepsy.1 In vivo, VPAwas found to be
associated with increased body weight, paralleled* Corresponding author at: Medical University Innsbruck, Anich-
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doi:10.1016/j.seizure.2008.03.002by hyperinsulinaemia, and decreased serum levels
of the insulin-sensitizing and anti-inflammatory adi-
pocytokine adiponectin in adults and children.2—4 In
vitro, adiponectin mRNA gene expression was sup-
pressed following VPA treatment in 3T3-L1 adipo-
cytes and C57BL/6J mice.5 Topiramate (TPM), a
sulfamate-substituted monosaccharide, is approved
for the treatment of selective seizure disorders.6 In
vivo, weight loss has been noted after TPM treat-
ment7 and studies in female Zucker diabetic fatty
(ZDF) rats demonstrated that TPM treatment leads. Published by Elsevier Ltd. All rights reserved.
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levels.8 In vitro, insulin-sensitizing effects of TPM
have been observed in liver, skeletal muscle and
adipose tissues.9 In contrast to VPA, adiponectin
mRNA concentration and secretion was increased
in 3T3-L1 adipocytes stimulated with TPM.9
Adipose tissue acts as an endocrine organ and
releases different factors into the circulation, col-
lectively referred to as adipocytokines (e.g. adipo-
nectin, leptin).10 Adiponectin has attracted much
attention as an adipocytokine with antidiabetic and
antiatherogenic properties with reduced concentra-
tions in individuals who are overweight, have car-
diovascular diseases or Type 2 diabetes.11,12 To date,
adiponectin is generally agreed to exert its biologi-
cal effects by interacting with the adiponectin
receptors, adipoR1 and adipoR2, mediating
increased AMP-activated protein kinase and peroxi-
some proliferator-activated receptor alpha ligand
activities as well as fatty acid oxidation and glucose
uptake.13 AdipoR1 is mainly expressed in the liver,
skeletal muscle and pancreas and binds the globular
form of adiponectin with high affinity, whereas
adipoR2 is predominantly expressed in the liver
exhibiting intermediate affinity to ligands.14
The direct effect of VPA and TPM on the adipo-
nectin receptor system in an adiponectin-free in
vitro model has not been investigated so far. The
aim of this study was to evaluate the influence of
VPA and TPM on adipoR1 and adipoR2 in human liver
cancer cells, HepG2.Methods
Cell culture
HepG2 cells were obtained from American type
Culture Collection (Manassas, VA) and were main-
tained in culture flasks at 37 8C at 5% CO2/95% air in
DMEM (Sigma, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum, 2% antibiotic solution
(Gibco, Paisley, Scotland) containing penicillin G
sodium/streptomycin sulfate and 1% glutamine. At
confluence, all treatments were carried out after
serum starvation. Valproic acid sodium salt was
obtained from Sigma and dissolved in dimethyl-
sulphoxide (Sigma). Topiramate was a kind gift of
Janssen-Cilag AG (Schaffhausen, Swizerland).
HepG2 cells were exposed to VPA for 6 h and 12 h
at concentrations of 0.1 mM, 0.5 mM, 1 mM, and
5 mM or to TPM for 12 h, 24 h, and 48 h at concen-
trations of 4 mM and 40 mM, respectively. In addi-
tion, TPM stimulation was performed in a
suprapharmacological concentration of 400 mM for
12 h. The incubation conditions and concentrationsof VPA or TPM are indicated in the figure legends and
performed as published previously.9,15,16
Viability tests showed increased LDH levels in
supernatants of cells incubated with VPA for longer
than 12 h, indicating toxic effects of VPA on HepG2
cell line after exposure periods longer than 12 h.
Analysis of adipoR1 and adipoR2 mRNA
synthesis
Total RNA isolation from HepG2 cells was performed
using the GenElute Mammalian Total RNA Kit
(Sigma). 1 mg of RNA was reverse-transcribed using
the Omniscript RT Kit (Quiagen, Hilden, Germany).
Ten percent of each reverse transcription reaction
was amplified.
MRNA of adipoR1 and adipoR2 were estimated by
quantification of adipoR1, adipoR2 and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA by
the TaqMan real time polymerase chain reaction
(PCR) (Perkin Elmer, Vienna, Austria) method
expressed as adipoR1/GAPDH cDNA ratio and adi-
poR2/GAPDH cDNA ratio. Real-time PCR was per-
formed as described in detail previously.17
Statistical analysis
SPSS (Version 15.0) was used for statistical analysis.
The Mann-Whitney U-test was used to determine
significant differences between groups. Statistical
significance was accepted at a P-value of less than
0.05. Unless otherwise mentioned, all values are
presented as means  S.E.M.Results
Upregulation of adipoR1/GAPDH cDNA ratio was
found after treatment with 0.1 mM and 0.5 mM
VPA, reaching statistical significance at a concen-
tration of 0.1 mM VPA after 6 h exposure period and
a 2.5-fold increase at a concentration of 0.5 mM VPA
after 12 h exposure period (Fig. 1A). Furthermore,
AdipoR1/GAPDH ratios were significantly increased
after treatment with 1 mM and 5 mM VPA after 6 h
and 12 h exposure period. Highest concentrations
with an almost 2.5-fold and an almost 4-fold
increase were observed after 12 h incubation period
with 1 mM and 5 mM VPA, respectively (Fig. 1A).
AdipoR2/GAPDH cDNA ratios tended to increase
during VPA stimulation though not reaching statis-
tical significance (Fig. 1B).
TPM stimulation neither affected the adipoR1/
GAPDH cDNA ratio nor the adipoR2/GAPDH cDNA
ratio, respectively, at concentrations and exposure
times tested.
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Figure 1 HepG2 cells were cultured and then incubated
without (0 mM VPA) or with valproic acid as indicated. (A)
Adiponectin receptor 1/GAPDH ratio and (B) adiponectin
receptor 2/GAPDH ratio relative to that in the control
(0 mM VPA) cells. Results are means  S.E.M. of separate
experiments. *p < 0.05.Discussion
This is the first study investigating the effect of VPA
and TPM on the adiponectin receptor system in
human liver cancer cells. The most important find-
ing is that VPA but not TPM increases adipoR1 mRNA
expression in an adiponectin-free in vitro model.
The most common adverse effects of VPA treat-
ment are weight gain, hyperinsulinemia, hyperlep-
tinemia and hypoadiponectinemia, limiting its use in
clinical practice, especially in children.3,4,18,19
However, the precise mechanisms underlying VPA-
associated metabolic side effects remain unclear.
TPM treatment, on the other hand, has been
reported to be associated with a decrease in body
weight and an improvement of glycaemic home-
ostasis.7
Beside its function as energy storage, adipose
tissue releases different factors (e.g. adipocyto-kines) into the circulation. Adipocytokines and
their receptor system have recently been sug-
gested as a link between body fat and glucose
metabolism.20,21 Adiponectin, as an adipocyte-
derived hormone, plays a critical role in the devel-
opment of type 2 diabetes and insulin resistance
(IR).20,21 AdipoR1 and adipoR2 serve as receptors
for adiponectin and are positively correlated to
adiponectin sensitivity.22 Of note, a number of
recent studies, which have focused on the rela-
tionship between adipoR1/R2 and insulin sensitiv-
ity, indicated that adipoR1, but not adipoR2, is
involved in glucose or lipid metabolism.23,24 Adi-
poR1 was found to be correlated with insulin
and C-peptide concentrations in vivo, and was
found to be a determinant of first-phase insulin
secretion independent of body fat.24 Furthermore,
levels of adipoR1 mRNA were increased 2.5-fold in
skeletal muscle cells of streptozotocin diabetic
mice.23
In this study, the effect of VPA and TPM on
adiponectin receptor mRNA expression in human
hepatoma cell line HepG2 was investigated. VPA
treatment increases adipoR1 mRNA expression
whereas adipoR2 mRNA expression tends to increase
without reaching statistical significance (see Fig. 1A
and B), excluding compensatory downregulation of
adipoR2/GAPDH cDNA ratios for the increased adi-
poR1/GAPDH cDNA ratios.
Due to the experimental design of this study and
the absence of adiponectin production in the liver,
we speculate on a direct effect of VPA on the
adiponectin receptor system in HepG2 cells. Since
adiponectin mRNA expression is known to be down-
regulated following VPA treatment in vivo2,4 and in
vitro5, increased adipoR1 mRNA expression in liver
cells possibly represents a favoured reaction balan-
cing suppressed adiponectin secretion from adipo-
cytes. Hypothetically, upregulation of adipoR1
mRNA expression increases adiponectin-binding
capacity leading to an insulin-sensitizing effect
and an increased ß-oxidation of free fatty acids
mediated through increased adiponectin action.
Changes concerning this equilibrium of receptor/
ligand expression in different compartments (e.g.
liver, muscle) might contribute to changes in fatty
acid oxidation, glucose uptake, obesity-linked IR
and the metabolic syndrome in VPA-treated
patients. This hypothesis is supported by the differ-
ential regulation of serum adiponectin concentra-
tions in overweight and lean VPA-treated children.4
In contrast to VPA, TPM did neither affect adipoR1
nor adipoR2 mRNA expression. This is similar to
current studies, where TPM treatment was found
to lead to enhanced muscle, but not liver, insulin
sensitivity.9
726 M. Rauchenzauner et al.The main limitation of this in vitro study is that
post-receptor processing as well as the influence of
VPA on insulin-signalling or its receptor expression in
parallel to adipoR1/R2 mRNA expression are
unknown.
In conclusion, this is the first study indicating an
upregulation of adiponectin receptor gene expres-
sion by VPA, but not by TPM, in vitro. Given the tight
association between VPA treatment, metabolic side
effects and the adipocytokine-axis, upregulation of
adipoR1 may represent a favoured and insulin-sensi-
tizing mechanism. Further in vitro and in vivo studies
should investigate the effect of VPA on insulin-signal-
ling, insulin-resistance inducing factors and the adi-
ponectin receptor system in muscle cells.References
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